<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Glenmark Pharmaceuticals Limited — News on 6ix</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited</link>
<description>Latest news and press releases for Glenmark Pharmaceuticals Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 12:50:56 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/glenmark-pharmaceuticals-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364b7178dffbe2df153502.webp</url>
<title>Glenmark Pharmaceuticals Limited</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited</link>
</image>
<item>
<title>Press Release Apr 09 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-apr-09-2026-15</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-apr-09-2026-15</guid>
<pubDate>Thu, 09 Apr 2026 12:50:56 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 09, 2026, titled "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg".</description>
</item>
<item>
<title>Press Release Apr 01 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-apr-01-2026-27</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-apr-01-2026-27</guid>
<pubDate>Wed, 01 Apr 2026 21:30:42 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS in the U.S., Significantly Expanding its Innovative Portfolio. RYALTRIS is Glenmark s first innovative product introduced into the U.S. market".</description>
</item>
<item>
<title>Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/glenmark-pharmaceuticals-announces-strategic-shift-to-direct-commercialization-and-distribution-of-ryaltrisr-in-the-us-significantly-expanding-its-innovative-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/glenmark-pharmaceuticals-announces-strategic-shift-to-direct-commercialization-and-distribution-of-ryaltrisr-in-the-us-significantly-expanding-its-innovative-portfolio</guid>
<pubDate>Wed, 01 Apr 2026 12:15:00 GMT</pubDate>
<description>Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray in the United States, effective April 1, 2026.</description>
</item>
<item>
<title>Press Release Mar 21 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-21-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-21-2026-5</guid>
<pubDate>Sat, 21 Mar 2026 04:28:57 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Glenmark Pharmaceuticals Launches GLIPIQ (Semaglutide) In India. Setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at Rs. 325".</description>
</item>
<item>
<title>Press Release Mar 19 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-19-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-19-2026-4</guid>
<pubDate>Thu, 19 Mar 2026 12:37:46 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg".</description>
</item>
<item>
<title>Press Release Mar 16 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-16-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-16-2026-2</guid>
<pubDate>Mon, 16 Mar 2026 12:43:32 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launchPotassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials".</description>
</item>
<item>
<title>Press Release Mar 04 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-04-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-mar-04-2026-4</guid>
<pubDate>Wed, 04 Mar 2026 13:36:45 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity".</description>
</item>
<item>
<title>Press Release Feb 27 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-feb-27-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-feb-27-2026-4</guid>
<pubDate>Fri, 27 Feb 2026 14:19:43 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials".</description>
</item>
<item>
<title>Press Release Jan 30 2026</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-jan-30-2026-15</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-jan-30-2026-15</guid>
<pubDate>Sat, 31 Jan 2026 01:13:05 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Press Release and Management Discussion & Analysis"".</description>
</item>
<item>
<title>Press Release Dec 23 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-23-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-23-2025-4</guid>
<pubDate>Tue, 23 Dec 2025 13:42:45 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP,30 mg/30 mL (1 mg/mL) Multiple-Dose Vial".</description>
</item>
<item>
<title>Press Release Dec 16 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-16-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-16-2025-7</guid>
<pubDate>Tue, 16 Dec 2025 20:35:00 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma".</description>
</item>
<item>
<title>Press Release Dec 11 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-11-2025</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-dec-11-2025</guid>
<pubDate>Thu, 11 Dec 2025 13:42:02 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial".</description>
</item>
<item>
<title>Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/cosmo-and-glenmark-announce-market-authorisation-of-winlevir-clascoterone-10-mgg-cream-for-treatment-of-acne-in-17-countries-in-europe-1</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/cosmo-and-glenmark-announce-market-authorisation-of-winlevir-clascoterone-10-mgg-cream-for-treatment-of-acne-in-17-countries-in-europe-1</guid>
<pubDate>Mon, 01 Dec 2025 14:30:00 GMT</pubDate>
<description>Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Glenmark Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.</description>
</item>
<item>
<title>Press Release Nov 27 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-27-2025-4</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-27-2025-4</guid>
<pubDate>Thu, 27 Nov 2025 15:15:22 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility".</description>
</item>
<item>
<title>Press Release Nov 25 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-25-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-25-2025-2</guid>
<pubDate>Tue, 25 Nov 2025 13:59:35 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Glenmark Pharmaceuticals Announces Launch of Nebzmart® GFB Smartules® and GlenmarkAirz® FB Smartules®, World s First Nebulized Triple Therapy for COPD".</description>
</item>
<item>
<title>Press Release Nov 18 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-18-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-18-2025-1</guid>
<pubDate>Tue, 18 Nov 2025 19:40:35 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2025, titled "Cosmo and Glenmark Announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe ".</description>
</item>
<item>
<title>Press Release Nov 14 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-14-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-14-2025-10</guid>
<pubDate>Fri, 14 Nov 2025 23:04:04 GMT</pubDate>
<description>Press Release and Management Discussion & Analysis - Q2FY26 Results</description>
</item>
<item>
<title>Press Release Nov 10 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-10-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-10-2025-8</guid>
<pubDate>Mon, 10 Nov 2025 20:30:08 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 10, 2025, titled "Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership".</description>
</item>
<item>
<title>Press Release Nov 04 2025</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-04-2025-13</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/press-release-nov-04-2025-13</guid>
<pubDate>Tue, 04 Nov 2025 13:57:35 GMT</pubDate>
<description>Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial".</description>
</item>
<item>
<title>Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial</title>
<link>https://6ix.com/company/glenmark-pharmaceuticals-limited/news/glenmark-pharmaceuticals-inc-usa-to-launch-84percent-sodium-bicarbonate-injection-usp-50-meq50-ml-1-meqml-single-dose-vial</link>
<guid isPermaLink="true">https://6ix.com/company/glenmark-pharmaceuticals-limited/news/glenmark-pharmaceuticals-inc-usa-to-launch-84percent-sodium-bicarbonate-injection-usp-50-meq50-ml-1-meqml-single-dose-vial</guid>
<pubDate>Tue, 04 Nov 2025 13:15:00 GMT</pubDate>
<description>Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin</description>
</item>
</channel>
</rss>